IFNG and Nail dystrophy: Similarly to a previous report, ruxolitinib treatment of five APECED patients led to clinical remission of multiple autoimmune manifestation like alopecia, oral candidiasis, nail dystrophy, gastritis, enteritis, arthritis, Sjögren's-like syndrome, urticaria, and thyroiditis and biochemical correction of the excessive IFN-γ signature [82▪▪].